ISSN: 0975-833X

Available online at http://www.journalcra.com

International Journal of Current Research
Vol. 17, Issue, 03, pp.32234-32236, March, 2025
DOI: https://doi.org/10.24941/ijcr.48581.03.2025

INTERNATIONAL JOURNAL OF CURRENT RESEARCH

RESEARCH ARTICLE

3D BIOPRINTING OF TUMOR MODELS FOR IMMUNOTHERAPY: A REVIEW ON NEXT-GENERATION APPROACHES IN CANCER DRUG TESTING

Karra Geetha*[1], Atchula Sripriya[2], Madhavaneni Shishla[2], Kandi Sandhya Devi[2] and Rama Rao, T.[3]

[1]Department of Pharmaceutics, CMR College of Pharmacy, Hyderabad, India, 501401; [2]Department of Pharm D, CMR College of Pharmacy, Hyderabad, India, 501401; [3]Department of Pharmaceutical Chemistry, CMR College of Pharmacy, Hyderabad, India, 501401

ARTICLE INFO

Article History:
Received 20th December, 2024
Received in revised form
19th January, 2025
Accepted 26th February, 2025
Published online 30th March, 2025

Key words:
Bioink, Cancer, Immune-tumor, Immunotherapies, Tumor Microenvironment (TME).

ABSTRACT

The advent of 3D bioprinting has transformed cancer research by enabling the creation of physiologically relevant tumor models. These models replicate the tumor microenvironment (TME) with high precision, allowing for more accurate testing of immunotherapeutic agents. This review explores key advancements in bioprinting technologies, bioink formulations, and immune cell integration within printed tumor models. The development of patient-specific models and artificial intelligence (AI)-driven bioprinting techniques has further enhanced the personalization of cancer treatment. Future directions focus on vascularization and the integration of bioprinted models with organ-on-a-chip systems, promising more effective drug screening and personalized therapeutic strategies.

Corresponding author:** ***Karra Geetha

Citation: Karra Geetha, Atchula Sripriya, Madhavaneni Shishla, Kandi Sandhya Devi and Rama Rao, T. 2025. *"*3D Bioprinting of Tumor Models for Immunotherapy: A Review on Next-Generation Approaches in Cancer Drug Testing*". International Journal of Current Research, 17, (03), 32234-32236.*

INTRODUCTION

The Need for Improved Tumor Models in Immunotherapy Research: Traditional preclinical models, such as 2D cell cultures and animal studies, have significant limitations in replicating the human TME. These models fail to capture the complexity of immune-tumor interactions, leading to discrepancies in drug efficacy between preclinical and clinical settings. The emergence of 3D bioprinting addresses these gaps by incorporating stromal, immune, and vascular components, thereby improving the predictive accuracy of therapeutic responses[1,2].

Limitations of 2D Cultures and Animal Models: While 2D cultures offer a controlled environment for studying tumor biology, they lack spatial organization and the ability to mimic tumor heterogeneity. Similarly, animal models often exhibit interspecies differences, making it challenging to translate findings to human patients. These limitations highlight the necessity for 3D bioprinted tumor models that better represent human physiology[3].

Role of 3D Bioprinting in Cancer Research: 3D bioprinting allows for the layer-by-layer deposition of cells and biomaterials to reconstruct tumor architecture. This technology facilitates the inclusion of various cell types and extracellular matrix (ECM) components, bridging the gap between simplistic preclinical models and complex human tumors[4].

Fundamentals of 3D Bioprinting in Cancer Research

3D Bioprinting Technologies

- **Extrusion-Based Bioprinting**: Utilizes pneumatic or mechanical pressure to extrude bioinks, making it suitable for printing high-viscosity materials and vascularized structures[5].
- **Inkjet-Based Bioprinting**: Involves thermal or acoustic forces to deposit droplets of cell-laden bioinks, allowing for rapid and cost-effective printing[5,6].
- **Laser-Assisted Bioprinting**: Uses laser-induced forward transfer to achieve high-resolution cell patterning while minimizing cell damage[5,7].

Bioinks for Tumor Modeling: Bioinks play a crucial role in maintaining cell viability and mimicking the tumor microenvironment. Natural bioinks, such as collagen and alginate, offer biocompatibility, while synthetic bioinks, like polyethylene glycol (PEG), provide tunable mechanical

properties. The use of decellularized ECM-based bioinks enhances TME fidelity by preserving native biochemical cues[8].

Recreating the Tumor Microenvironment: To develop realistic tumor models, bioprinted constructs incorporate stromal cells (e.g., fibroblasts), immune cells (e.g., T cells), and vascular networks. These elements are critical for replicating tumor-immune interactions and studying resistance mechanisms to immunotherapies[9].

Incorporating Immune Cells into Bioprinted Tumors

Printing Tumor-Immune Models: Strategies for integrating immune cells into bioprinted tumors include direct co-printing and sequential culturing. Direct co-printing allows for precise spatial organization, while sequential culturing enables controlled immune cell infiltration. However, challenges such as maintaining immune cell viability post-printing persist and are being addressed through the development of oxygen-releasing bioinks[10].

Immune-Tumor Interactions: 3D bioprinted models enable in-depth studies of tumor-infiltrating lymphocytes (TILs) and immune checkpoint interactions (e.g., PD-1/PD-L1). These models provide insights into immunotherapy resistance mechanisms, helping refine therapeutic approaches[11.19].

Applications in Immunotherapy Drug Testing

Screening Checkpoint Inhibitors: Bioprinted tumor models offer a robust platform for evaluating checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors. These models simulate T-cell exhaustion and antigen presentation dynamics, improving the accuracy of preclinical drug screening[12].

CAR-T and TCR-T Cell Therapy: 3D bioprinted models facilitate the assessment of CAR-T and TCR-T cell therapies by evaluating immune cell infiltration and cytotoxicity in dense tumor tissues. These models help optimize T-cell engineering strategies to enhance therapeutic efficacy in solid tumors[13].

Personalized Tumor Models: By utilizing patient-derived cells, 3D bioprinting enables the creation of personalized tumor models. These models allow for individualized immunotherapy testing, advancing precision medicine by predicting patient-specific treatment responses[14,15,18,20].

Novel Approaches in 3D Bioprinting for Immuno-Oncology: Advancements in AI-driven bioprinting have accelerated the development of complex tumor models. Machine learning algorithms optimize bioink composition and printing parameters, improving the reproducibility and scalability of bioprinted constructs[15,16,17].

CONCLUSION

3D bioprinting has emerged as a powerful tool for replicating the tumor microenvironment, enhancing the study of immune-tumor interactions, and improving immunotherapy evaluation. Compared to traditional models, bioprinted tumors provide a more accurate representation of human cancer, reducing reliance on animal testing and improving translational relevance. However, challenges such as ensuring long-term tissue viability, standardizing bioink formulations, and addressing regulatory concerns remain key hurdles. Future research must prioritize the integration of vascularized bioprinted tumors with organ-on-a-chip platforms to facilitate high-throughput drug screening. Additionally, AI-driven approaches hold promise for optimizing bioprinting parameters and enhancing reproducibility. Addressing these challenges will be crucial for the clinical translation of bioprinted tumor models, ultimately paving the way for more effective and personalized cancer treatments.

REFERENCES

1. Zhang Z, Chen X, Gao S, Fang X, Ren S. 3D bioprinted tumor model: a prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment. Cellular Oncology. 2024 Mar 23.
2. Datta P, Dey M, Ataie Z, Unutmaz D, Ozbolat IT. 3D bioprinting for reconstituting the cancer microenvironment. NPJ Precision Oncology. 2020 Jul 27;4(1).
3. Zhuang X, Deng G, Wu X, Xie J, Li D, Peng S, et al. Recent advances of three-dimensional bioprinting technology in hepato-pancreato-biliary cancer models. Frontiers in Oncology. 2023 Apr 28;13.
4. Hagenbuchner J, Nothdurfter D, Ausserlechner Michael J. 3D bioprinting: novel approaches for engineering complex human tissue equivalents and drug testing. Jang J, editor. Essays in Biochemistry. 2021 Aug;65(3):417–27.
5. Iftekar SF, Aabid A, Amir A, Baig M. Advancements and Limitations in 3D Printing Materials and Technologies: A Critical Review. Polymers. 2023 Jan 1;15(11):2519.
6. Fang L, Liu Y, Qiu J, Wan W. Bioprinting and its Use in Tumor-On-A-Chip Technology for Cancer Drug Screening: A Review. International Journal of Bioprinting. 2022 Aug 16;8(4).
7. Chang J, Sun X. Laser-induced forward transfer based laser bioprinting in biomedical applications. Front Bioeng Biotechnol. 2023; 11:1255782. doi: 10.3389/fbioe. 2023. 1255782.
8. Wang H, Yu H, Zhou X, et al. An overview of extracellular matrix-based bioinks for 3D bioprinting. Front Bioeng Biotechnol. 2022; 10:905438. doi: 10.3389/ fbioe.2022.905438. (https://doi.org/10.3389/fbioe.2022.905438)
9. Kim S, Han S, Lee J, Lee C, Park S. Bioprinting of tumor immune microenvironment for immunotherapy. Int J Bioprinting. 2024;10(5):3988. doi: 10.36922/ijb.3988.
10. Rafique M, Ali O, Shafiq M, et al. Insight on oxygen-supplying biomaterials used to enhance cell survival, retention, and engraftment for tissue repair. Biomedicines. 2023; 11(6):1592. doi: 10.3390/ biomedicines 11061592.)
11. Gupta D, Chichkov B, Vereb ZJ, Ozbolat IT. Editorial: Innovative 3D technologies in cancer immunity research and therapy. Front Immunol. 2023; 14:1235483. doi:10.3389/fimmu.2023.1235483. (https://doi.org/10.3389/fimmu.2023.1235483)
12. Zhang Z, Chen X, Gao S, Fang X, Ren S. 3D bioprinted tumor model: A prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment. Cell Oncol (Dordr).

2024;47(4):1113-1126. [Correction appears in Cell Oncol (Dordr). 2024, 47(4), 1127]. doi: 10.1007/s13402-024-00935-9.

13. Tang Y, Yang X, Hu H, et al. Elevating the potential of CAR-T cell therapy in solid tumors: Exploiting biomaterials-based delivery techniques. Front BioengBiotechnol. 2024;11:1320807. doi: 10.3389/fbioe.2023.1320807.
14. Lam EHY, Yu F, Zhu S, Wang Z. 3D bioprinting for next-generation personalized medicine. Int J MolSci. 2023;24(7):6357. doi: 10.3390/ijms24076357.
15. Germain N, Dhayer M, Dekiouk S, Marchetti P. Current advances in 3D bioprinting for cancer modeling and personalized medicine. *Int J MolSci*. 2022; 23(7):3432. doi: 10.3390/ijms23073432. (https://doi.org/ 10.3390/ ijms23073432)
16. Manduca N, Maccafeo E, De Maria R, Sistigu A, Musella M. 3D cancer models: One step closer to in vitro human studies. Front Immunol. 2023; 14:1175503. doi: 10.3389/fimmu.2023.1175503. (https://doi.org/10.3389/ fimmu.2023.1175503)
17. Mladenovska T, Choong PF, Wallace GG, O'Connell CD. The regulatory challenge of 3D bioprinting. Regenerative Medicine. 2023;18(8):659-674. doi: 10.2217/rme-2022-0194. (https://doi.org/10.2217/rme-2022-0194)
18. Chliara MA, Elezoglou S, Zergioti I. Bioprinting on organ-on-chip: Development and applications. Biosensors (Basel). 2022; 12(12):1135. doi: 10.3390/bios12121135. (https://doi.org/10.3390/bios12121135)
19. Miri AK, Mostafavi E, Khorsandi D, Hu SK, Malpica M, Khademhosseini A. Bioprinters for organs-on-chips. Biofabrication. 2019; 11(4):042002. doi: 10.1088/1758-5090/ab2798. (https://doi.org/10.1088/1758-5090/ ab2 798)
20. Sharma R, Restan Perez M, da Silva VA, et al. 3D bioprinting complex models of cancer. *Biomater Sci*., 2023; 11(10):3414-3430. doi: 10.1039/d2bm02060b.

****